BRAFV600E is associated with higher incidence of second cancers in adults with Langerhans cell histiocytosis

Author(s):
Acosta-Medina, A.A.; Kemps, P.G. (0000-0001-9793-7032); Zondag, T.C.E.; Abeykoon, J.P.; Forma-Borst, J.; Steenwijk, E.C.; Feijen, E.A.M.; Teepen, J.C.; Bennani, N.N.; Schram, S.M.; Shah, M.; Davidge-Pitts, C.; Koster, M.J.; Ryu, J.H.; Vassallo, R.; Tobin, W.O.; Young, J.R.; Dasari, S.; Rech, K.; Ravindran, A.; Cleven, A.H.G.; Verdijk, R.M.; Noesel, C.J.M. van; Balgobind, B.; Bouma, G.J.; Saeed, P.; Bramer, J.A.M.; Groen, R.A.L. de; Vermaat, J.S.P.; Sande, M.A.J. van de; Smit, E.F.; Langerak, A.W.; Wezel, T. van; Tonino, S.H.; Bos, C. van den; Laar, J.A.M. van; Go, R.S.; Goyal, G.; Halteren, A.G.S. van
Published
2023
Publication type
Article / Letter to editor

Abstract

In this retrospective study, BRAF mutation status did not correlate with disease extent or (event-free) survival in 156 adults with Langerhans cell histiocytosis. BRAFV600E was associated with an increased incidence of second malignancies, often comprising hematological cancers, which may be clonally related.

Date issued
2023-11-02
Language
English
Publisher
American Society of Hematology (ASH Publications)
Is part of
Blood (2023), Vol. 142, no. 18, p. 1570-1575
hdl
1887/4302386
doi
10.1182/blood.2023021212